Skip to main content

Table 2 Baseline characteristics for pediatric patients

From: Impact of viral multiplex real-time PCR on management of respiratory tract infection: a retrospective cohort study

 

Missing

Total

Viral a

Any virus b

Other c

p-value d

values

(n = 72)

(n = 40)

(n = 45)

(n = 32)

Viral vs. any virus

Viral vs. other

Demographics

 Age, mean years ± SD (range)

 

4.9 ± 5.7 (0–17)

4.3 ± 5.4 (0–16)

4.7 ± 5.5 (0–16)

5.7 ± 6.0 (0–17)

0.74

0.30

 Female sex, n (%)

 

31 (43.1)

14 (35.0)

18 (40.0)

17 (53.1)

0.64

0.13

 Outpatients, n (%)

 

3 (4.2)

2 (5.0)

2 (4.4)

1 (3.1)

1.00

1.00

Comorbidities, n (%)

 Asthma

 

1 (1.4)

1 (2.5)

1 (2.2)

0 (0.0)

1.00

1.00

 Other chronic lung diseasee

 

13 (18.1)

7 (17.5)

8 (17.8)

6 (18.8)

0.97

0.89

 Solid cancerf

 

1 (1.4)

0 (0.0)

0 (0.0)

1 (3.1)

n/a

0.89

 Haematologic malignancy

 

10 (13.9)

8 (20.0)

9 (20.0)

2 (6.3)

1.00

0.18

 Organ transplantation

 

1 (1.4)

1 (2.5)

1 (2.2)

0 (0.0)

1.00

1.00

 Neutropenia

 

9 (12.5)

8 (20.0)

8 (17.8)

1 (3.1)

0.79

0.06

 Systemic steroids

 

8 (11.1)

5 (12.5)

6 (13.3)

3 (9.4)

0.91

0.98

 Other Immunosuppressiong

 

3 (4.2)

3 (7.5)

3 (6.7)

0 (0.0)

1.00

0.33

Clinical findings

 Systolic blood pressure, mmHg, mean ± SD (range)

29

100 ± 18 (59–140)

106 ± 15 (71–140)

105 ± 14 (71–140)

95 ± 18 (59–120)

0.82

0.04

 Heart rate, beats/min, mean ± SD (range)

3

136 ± 33 (60–234)

138 ± 32 (60–186)

134 ± 32 (60–186)

135 ± 35 (72–234)

0.58

0.71

 Respiratory rate, breaths/min, mean ± SD (range)

15

41 ± 20 (16–103)

41 ± 21 (18–103)

40 ± 21 (16–103)

40 ± 19 (16–88)

0.84

0.86

 Body temperature, °C, mean ± SD (range)

3

37.6 ± 1.1 (35.0–40.1)

37.5 ± 1.1 (35.0–39.5)

37.5 ± 1.1 (35.0–39.5)

37.7 ± 1.1 (35.1–40.1)

1.00

0.46

Laboratory findingsh, mean ± SD (range)

 C-reactive protein (maximum), mg/l

2

85 ± 141 (5–999)

62 ± 77 (5–291)

67 ± 81 (5–293)

113 ± 191 (7–999)

0.78

0.16

 White blood cells (maximum), G/l

2

16.0 ± 12.1 (0.2–63.1)

12.6 ± 10.0 (0.2–57.0)

13.6 ± 11.3 (0.2–57.0)

20.1 ± 13.3 (1.8–63.1)

0.68

0.01

 Platelets (minimum), G/l

2

246 ± 144 (15–674)

257 ± 175 (15–674)

244 ± 169 (15–674)

234 ± 96 (16–488)

0.73

0.49

Discharge diagnosis, n (%)

 Bronchitis

 

10 (13.9)

9 (22.5)

9 (20.0)

1 (3.1)

0.78

0.04

 Upper respiratory tract infection

 

14 (19.4)

9 (22.5)

10 (22.2)

5 (15.6)

0.98

0.47

 Respiratory tract infection, unspecified

 

4 (5.6)

4 (10.0)

4 (8.9)

0 (0.0)

1.00

0.18

 Community-acquired pneumonia

 

15 (20.8)

6 (15.0)

8 (17.8)

9 (28.1)

0.73

0.18

 Hospital-acquired pneumonia

 

10 (13.9)

5 (12.5)

6 (13.3)

5 (15.6)

0.91

0.96

 Aspiration pneumonia

 

2 (2.8)

1 (2.5)

2 (4.4)

1 (3.1)

1.00

1.00

 Otheri

 

17 (23.6)

6 (15.0)

6 (13.3)

11 (34.4)

0.83

0.06

  1. °C, degree Celsius, COPD chronic obstructive pulmonary disease, HIV human immunodeficiency virus, n number, SD standard deviation
  2. aCases in which only one or more respiratory viruses were detected
  3. bCases in which one or more respiratory viruses were detected (as single or mixed infection)
  4. cIncludes bacterial etiology, mixed etiology, no pathogen
  5. dFor continuous variables, 2-sample independent t-test was used. For categorical variables, Mantel-Haenszel chi square or Fisher exact test were used
  6. eOther chronic lung diseases, e.g. cystic fibrosis, pulmonary sarcoidosis, pulmonary hypertension
  7. fAll solid tumors including bronchial carcinoma
  8. gPatients with one of the following conditions: primary or secondary antibody deficiency, congenital immunodeficiency, immunosuppressive therapy other than steroids, severe malnutrition with cachexia
  9. hHighest/lowest value within a time period of 3 days before and 3 days after date of rtPCR
  10. iOther infections (n = 14); neoplastic diseases (n = 1); collagen vascular; other rheumatologic or autoimmune (n = 1); gastroesophageal diseases (n = 1)
Back to article page

Pneumonia

ISSN: 2200-6133

Contact us